PeptiDream has expanded its partnership with Novartis previously signed in 2019 for the discovery of peptides to be used as peptide-drug conjugate
The partnership will leverage PeptiDream’s Peptide Discovery Platform System (PDPS) technology to discover new macrocyclic peptides for Novartis-selected targets to be used in radionuclide conjugation and other therapeutic/diagnostic applications
Under the partnership, PeptiDream is entitled to receive $180M upfront, $2.71B development, regulatory & commercial milestones along with net-sales-based tiered royalties
Ref: PeptiDream | Image: Novartis
Related News:- PeptiDream Signs a Multi-Target Collaboration and License Agreement with Genentech to Discover and Develop Novel Peptide-Radioisotope Drug Conjugates
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
